The methods to target TGF-β include pan-TGF-β neutralising antibodies, antisense TGF-β oligonucleotides, and TGF-βR1 inhibitors; however, the results from trials in GBM patients have been disappointing and further highlight the importance of targeting multiple pathways to derive a clinical benefit in GBM patients [76]. The gene discussed is TGFB1; the disease is glioblastoma.